Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Protocell synthetic biology === The in vitro generation of synthetic cells is the protocell branch of synthetic biology. Lipid vesicles, which have all the necessary components to function as a complete system, can be used to create these artificial cells. In the end, these synthetic cells should meet the requirements for being deemed alive, namely the capacity for self-replication, self-maintenance, and evolution. The protocell technique has this as its end aim, however there are other intermediary steps that fall short of meeting all the criteria for a living cell. In order to carry out a specific function, these lipid vesicles contain cell extracts or more specific sets of biological macromolecules and complex structures, such as enzymes, nucleic acids, or ribosomes. For instance, liposomes may carry out particular polymerase chain reactions or synthesise a particular protein. Innovations in synthetic biology have led to the development of organelle-like scaffolds using phase-separated biomolecular condensates to compartmentalize cellular processes in Escherichia coli, such as RNA-based TEARS. These membraneless organelles can be engineered to scaffold metabolic pathways, or enabling protein purification with no traditional external chromatography materials by a workflow termed PandaPure.
== Judicial process == Ba'athist Syria had a long history of arbitrary arrest, unfair trials and prolonged detention of suspects. Thousands of political prisoners remain in detention, with many belonging to the banned Muslim Brotherhood and the Communist Party. Since June 2000, more than 700 long-term political prisoners have been freed by President al-Assad, though an estimated 4,000 are reportedly still imprisoned. Information regarding those detained in relation to political or security-related charges is not divulged by the authorities. The government has not acknowledged responsibility for around 17,000 Lebanese citizens and Palestinians who "disappeared" in Lebanon in the 1980s and early 1990s and are thought to be imprisoned in Syria. In 2009, hundreds of people were arrested and imprisoned for political reasons. Military police were reported to have killed at least 17 detainees. Human rights activists are continually targeted and imprisoned by the government. On 18 September 2020, Netherlands demanded that the Syrian president Bashar al-Assad be held accountable for the war crimes and crimes against humanity committed during the civilian war. The Dutch officials sent a notice to the Syrian regime on the legal actions to be taken and submitted a case at the International Court of Justice on the Syrian government's failure to negotiate under the UN framework.
The cancerous skin lesions refer to damaged cutaneous tissues with risks of further developing into skin cell carcinoma. Skin carcinoma, or skin cancer, is very common in sun-radiation-abundant areas. The over-exposure to sunlight is the most prevalent cause that leads to Actinic keratosis (AK), a common cancerous cutaneous lesion. Photodynamic therapy (PDT) has proven to be an effective approach for AK at sites of poor healing with few responses to other therapies. In the comparison study between MAL-LEDT and typical cryotherapy, blue-light LEDT with Aminolevulinic acid (ALA) as a photosensitizer reveals significantly higher healing rates. The other clinical trial illustrates the effect of combined therapy of red-light LEDT and nano-emulsion in treating cancerous skin lesions.
Sources: en.wikipedia.org
== Sources == Meredith, Martin (2010). Mandela: A Biography. New York: PublicAffairs. ISBN 978-1-58648-832-1. Sampson, Anthony (2011) [1999]. Mandela: The Authorised Biography. London: HarperCollins. ISBN 978-0-00-743797-9.
sister chromatids A pair of identical copies (chromatids) produced as the result of the DNA replication of a chromosome, particularly when both copies are joined together by a common centromere; the pair of sister chromatids is called a dyad. The two sister chromatids are ultimately separated from each other into two different cells during mitosis or meiosis.
Unlike graphene, which is a two-dimensional semimetal, carbon nanotubes are either metallic or semiconducting along the tubular axis. For a given (n,m) nanotube, if n = m, the nanotube is metallic; if n − m is a multiple of 3 and n ≠ m, then the nanotube is quasi-metallic with a very small band gap, otherwise the nanotube is a moderate semiconductor. Thus, all armchair (n = m) nanotubes are metallic, and nanotubes (6,4), (9,1), etc. are semiconducting. Carbon nanotubes are not semimetallic because the degenerate point (the point where the π [bonding] band meets the π* [anti-bonding] band, at which the energy goes to zero) is slightly shifted away from the K point in the Brillouin zone because of the curvature of the tube surface, causing hybridization between the σ* and π* anti-bonding bands, modifying the band dispersion. The rule regarding metallic versus semiconductor behavior has exceptions because curvature effects in small-diameter tubes can strongly influence electrical properties. Thus, a (5,0) SWCNT that should be semiconducting in fact is metallic according to the calculations. Likewise, zigzag and chiral SWCNTs with small diameters that should be metallic have a finite gap (armchair nanotubes remain metallic). In theory, metallic nanotubes can carry an electric current density of 4 billion A/cm2, which is more than 1,000 times greater than those of metals such as copper, where for copper interconnects, current densities are limited by electromigration.
== Function == ADAMTS7 was identified as a protease that binds and cleaves COMP in a yeast two-hybrid screen using the epidermal growth factor (EGF) domain of COMP as the bait. However, this initial finding has been contested; a 2025 study demonstrated that purified ADAMTS7 does not exhibit proteolytic cleavage activity toward purified COMP. Furthermore, three independent unbiased N-terminal amine isotopic labeling of substrates (N-TAILS) proteomic studies identified a number of candidate substrates for ADAMTS7 but did not identify COMP as a potential substrate. Consequently, there is as yet no scientific consensus on the physiological function of ADAMTS7. Tissue inhibitor of metalloproteinases 4 (TIMP-4) appears to be the physiological inhibitor of ADAMTS7.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.